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Abstract. Aim: To test whether melatonin reduces oxidative
and inflammatory biomarkers in a closed-chest porcine model
of acute myocardial infarction. Materials and Methods: Twenty
pigs were randomized to receive a total dosage of 200 mg (0.4
mg/ml) of melatonin, or placebo immediately prior to
reperfusion of a coronary artery balloon occlusion in a
randomized, observer-blinded, placebo-controlled trial. We
assessed high-sensitivity troponin T (hs-TnT), malondialdehyde
and interleukin-1b, -6 and -10 at baseline, 30 min and 1, 2, 3
and 4 h after the start of reperfusion. Results: Seventeen pigs
completed the trial. There was an increase in hs-TnT, but no
significant difference between the melatonin-treated and
placebo-treated groups. There were no significant differences in
development of any of the circulating plasma markers between
the two groups. Conclusion: Melatonin treatment did not result
in reduction of inflammatory or oxidative stress markers after
experimental myocardial infarction compared to placebo.
Coronary heart disease and its most severe presentation,
acute ST-segment elevation myocardial infarction (STEMI)
is the leading cause of mortality and morbidity in the
Western world (1). Primary percutaneous coronary
intervention (pPCI) with restoration of coronary blood flow
is considered the optimal treatment-of-choice for STEMI (2).
However, the restoration of blood flow and concomitant re-
oxygenation of myocytes are frequently associated with an
exacerbation of tissue injury and a profound inflammatory
response called reperfusion injury (3).
Melatonin, (N-acetyl-5-methoxytryptamine), an endogenous
circadian hormone secreted by the pineal gland, is known to
protect against oxidative stress due to its direct free radical-
scavenging of reactive oxygen species (ROS) and its indirect
antioxidant actions by up-regulating antioxidant enzymes and
down-regulating pro-oxidant enzymes (4). Melatonin
possesses anti-inflammatory properties (4) and previous
experimental studies have shown it to reduce myocardial
ischemia-reperfusion (IR) injuries (5). In combination with its
low toxicity (6), this makes melatonin a promising candidate
with regard to potential treatment of IR injuries. 
The aim of the present study was to analyze the circulating
levels of oxidative (malondialdehyde, MDA) and inflammatory
[interleukin (IL)-1β, IL6 and IL10] biomarkers in a porcine
closed-chest model of STEMI and examine whether
intracoronary and systemic melatonin could reduce these
markers following reperfusion of the ischemic myocardium. 
Materials and Methods
The present study reports secondary outcomes from a randomized,
double-blind, placebo-controlled trial that primarily examined the
cardio protective effect of intracoronary (i.c.) and intravenous (i.v.)
melatonin in a clinically relevant in vivo closed-chest porcine model
of myocardial ischemia, during experimental STEMI and
reperfusion assessed by cardiac magnetic resonance (CMR) as will
be reported in another article (data not reported here). 
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Experimental procedure. In the closed-chest porcine model, we used a
group of 20 normally-fed, female, Danish Landrace pigs. The pigs
were premedicated with 4 ml intramuscular (i.m.) Zoletil (6.25 mg/ml
ketamine , 6.25 mg/ml tiletamin, 6.25 mg/ml zolazepam, 1.25 mg/ml
butorphanol and 6.5 mg/ml xylazin), intubated with cuffed
endotracheal tubes and mechanically ventilated with FiO2 0.5. The
ventilation was adjusted to obtain normocapnia (pCO2 4-6 kPa).
Anesthesia was maintained by inhalation of 1% isoflurane and
analgesia was assured by continuous infusion of 5 μl/ml fentanyl and
5 μl/ml midazolam at a rate of 8 ml/min, adjusted if needed.
Throughout the study, the pigs were continuously monitored by
electrocardiography, pulse oximetry and central body temperature.
Access to the central venous system was assured with a 7 Fr introducer
sheath in the femoral vein. Prior to arterial catheterization,
unfractionated heparin (single bolus, 5,000 units) was administered i.v.
During the pre-ischemic period, baseline values were recorded.
Under X-ray guidance, a 6 Fr PCI-guiding catheter inserted
through a 9 Fr introducer sheath was placed in the left coronary
ostium through the femoral artery. A baseline coronary angiogram
was performed using the contrast agent Iomeron (300 mg/ml). An
over-the-wire 6 Fr PCI-catheter (Apex OTW balloon catheter; Boston
Scientific, Natick, MA, USA) was placed in the left anterior
descending artery or the circumflex coronary artery under X-ray
guidance. Under angiographic control, absolute ischemia was induced
by inflation of the angioplasty balloon at submaximal, but just
occlusive pressure. The occlusive inflation of the balloon was kept
unchanged for 45 minutes. If the animals during the experimental
protocol suffered from ventricular fibrillation a biphasic defibrillator
(360 J) was used for cardioversion. Changes in the electrocardiogram
additionally verified the occlusion. Following 45 min of total
occlusion, the myocardium was reperfused for four hours before the
animal was euthanized and the heart was explanted.
Intervention procedure. The 20 pigs were randomized to receive either
i.v. and i.c. melatonin (0.4 mg/ml) approximately 5 mg/kg, or i.v. and
i.c. placebo (isotonic saline, 0.9 mg/ml). Five minutes prior to
reperfusion an i.v. infusion of 198 mg melatonin diluted in isotonic
saline (0.4 mg/ml) or placebo, 495 ml isotonic saline, was started.
Total i.v. infusion time was 30 min. One minute prior to reperfusion
a bolus of 5 ml containing 2 mg melatonin diluted in isotonic saline
(0.4 mg/ml) or placebo, 5 ml isotonic saline, was slowly injected
through the central lumen of the over-the-wire catheter directly into
the coronary artery. Total i.c. infusion time was 2 min and the infusion
lasted during the first minute of reperfusion. Throughout the study,
the experimenters were blinded with regard to the drug administered.
Blood sampling. Blood samples were collected from a catheter in
the femoral vein at baseline at 30 min and 1, 2, 3 and 4 h after the
start of the reperfusion and analyzed for high-sensitivity troponin T
(hs-TnT), oxidative stress marker, MDA, and inflammatory markers,
IL1β, IL6 and IL10. 
Hs-TnT in blood samples. For the determination of hs-TnT, the
levels in plasma were analyzed immediately after sampling. We
used the Cobas e 601 instrument (Roche Diagnostic, Hvidovre,
Denmark) with a detection range of 3-10,000 ng/l.
Oxidative stress markers in blood samples. For the determination of
the concentration of MDA, blood was drawn into tubes containing
heparin-free lipopolysaccharide and centrifuged at 3,100 rpm 
(3,000 G) for 3 min and then stored at −80˚C until analysis. MDA
was analyzed using a high-performance liquid chromatograph
method as described previously (7). 
Inflammatory markers in blood samples. For the determination of
pro- and anti-inflammatory cytokines, blood was drawn into tubes
containing EDTA, and centrifuged at 3,100 rpm (3000 G) for 3 min
and then stored at −80˚C until analysis. IL6 and IL1βconcentrations
in serum were determined by sandwich enzyme-linked
immunosorbent assays from R&D Systems Europe Ltd, Abingdon,
Oxon, United Kingdom (Duoset DY686, Duoset DY681 and Duoset
DY693B, respectively). These use goat anti pig IL6/IL1β/IL10 for
catching, and biotinylated goat anti pig IL6/IL1 β /IL10 for
detection including a porcine IL6/IL1β/IL10 standard. Development
of plates was done with a tetramethylbenzidine peroxide color
substrate from KemEnTec (Taastrup, Denmark), following the
manufacturer’s instructions. Samples were run in duplicates in a
dilution of 1:2 with a detection limit of 62.5 pg/ml (IL6), 31.3 pg/ml
(IL1β), and 46.9 pg/ml (IL10).
Ethics. The study was performed in accordance with the Guide for
the Care and Use of Laboratory Animals (NIH publication no. 85-
23, revised 1996) (8) and approved by the Danish Animal
Experiments Inspectorate, license no. 2012-15-2934-00583.
Sample size. The sample size calculation for the primary outcome
(CMR) was based on a previous trial reporting primary outcome
(infarct size relative to the area at risk), assessed by ex vivo CMR
imaging. Primary outcome was reduced from 74.1±8.2 % to
58.3±9.6% of the area at risk (mean±SD, SD converted from SEM)
(9). With a power of 90% and a type I error of 5%, a sample size of
seven pigs were needed in each treatment arm. We chose to include
10 pigs in each group, due to an expected waste of one or two pigs
in each arm. 
For the secondary outcomes reported in this article, we conducted
a post-hoc sample size calculation based on MDA in plasma
measured at reperfusion in an open-chest porcine model (10). This
study reported a mean±SD of 3.55±0.18 and 3.3±0.13 nmol MDA/l
for the control group and intervention group, respectively. Thus, with
a power of 90% and a type I error of 5%, the sample size calculation
revealed that we would need 18 pigs in total, nine in each arm.
Statistics. Data were analyzed using non-parametric methods after
testing for normality using the Kolmogorov-Smirnov test. Data for
change over time were analyzed using Friedman analysis of
variance and data between groups were analyzed using
Mann–Whitney U-test. Data are presented as median (interquartile
range, IQR). Results with p-values less than 0.05 were considered
statistically significant. Data were analyzed using SPSS version 20
software (SPSS, Chicago, IL, USA). 
Results
Of the 20 animals entering the study, three died (2 pigs in
the melatonin group and 1 pig in the placebo group) due to
irreversible ventricular fibrillation during the balloon
occlusion. Thus, 8 pigs randomized to melatonin and 9 pigs
randomized to placebo completed the experimental protocol
and were included in the final analysis.
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A total of 15 pigs had an occlusion of the circumflex artery,
while 2 pigs had an occlusion of the left anterior descending
artery. Three pigs in the melatonin group and 4 pigs in the
placebo group experienced ventricular tachycardia. In the
placebo group 1 pig was defibrillated due to ventricular
fibrillation. No significant difference was observed between the
melatonin group and the placebo group with respect to duration
of anesthesia [melatonin: 382 (351-445) min vs. placebo: 375
(364-426) min, p=0.96] or duration of the reperfusion period
[melatonin: 4 (4-4) h vs. placebo: 4 (4-4) h, p=1.00].
hs-TnT in blood samples. Baseline hs-TnT levels were 0 (0-13)
ng/l in both the placebo and melatonin group. In both treatment
arms, we found the highest increase in hs-TnT 2 h after the
start of reperfusion, representing a myocardial infarction: 5,881
(1398-9158) ng/l in the placebo group versus 3,413 (2389-
6326) ng/l in the melatonin group (p=0.63).
Oxidative stress marker in blood samples. There was no
significant difference in development of MDA levels over time
in the melatonin group or the placebo group (p=0.06 and
p=0.23, respectively) (Figure 1). There was no significant
difference in MDA levels between the melatonin and the
placebo group at 4 h of reperfusion (p=0.6) (Figure 1).
Inflammatory markers in blood samples. When analyzing
IL1β, Il6 and IL10 we found no significant difference in
development of levels over time in neither the melatonin
(p=0.25, 0.08 and 0.08, respectively), nor the placebo group
(p=0.11, 0.13 and 0.14, respectively) (Figure 2).
There was no significant difference in any of the pro-
(IL1β, IL6) or anti-inflammatory (IL10) markers between the
melatonin and the placebo group at four hours of reperfusion
(p=1.0, 0.39 and 0.35, respectively) (Figure 2). 
Discussion
In the present study, we aimed to analyze circulating levels
of oxidative and inflammatory biomarkers after myocardial
ischemia and subsequent reperfusion, and examine whether
melatonin could reduce the production of these markers in a
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Figure 1. MDA measured in plasma at baseline and up to 4 h of
reperfusion of the pigs receiving melatonin or placebo. Curve chart with
median (lines) and interquartile ranges, IQR (bars). Thick error bars
represent IQR of the melatonin data. BL=Baseline.
Figure 2. Cytokines measured in plasma at baseline and up to 4 h of
reperfusion of the pigs receiving melatonin or placebo. Curve chart with
median (lines) and interquartile ranges, IQR, (bars). Thick error bars
represent IQR of the melatonin data. IL-1β=Interleukin-1β, IL-
6=Interleukin-6, IL-10=Interleukin-10.
porcine closed-chest model. However, in our setup, 
45 min of myocardial ischemia did not appear to produce a
reperfusion injury that could be measured by a broad range
of oxidative and inflammatory markers up to 4 h after the
start of the reperfusion. Consequently, it was not possible to
demonstrate whether melatonin reduced the systemic
inflammatory and oxidative stress response following a
coronary artery occlusion.
The closed-chest porcine model has proven to be
superior in interventional studies of IR injury (11), because
of the anatomical, physiological and pathological
similarities to the human heart (12). Myocardial IR injury
involves a number of pathophysiological mechanisms such
as endothelial dysfunction, intracellular calcium overload,
dissipation of mitochondrial membrane potential and
immune activation (13). Furthermore, a pivotal mechanism
in myocardial IR injury is the generation of oxygen
metabolites, in particular reactive oxygen species, which
can lead to DNA damage, lipid peroxidation, protein
oxidation and mitochondrial permeability transition (14,
15). The imbalance between ROS production and
antioxidant defenses leads to the condition known as
oxidative stress (16). ROS and lipid peroxides are short-
lived and difficult to measure directly. Thus MDA, a
degradation product of lipid peroxides, is often used as a
surrogate reflecting the lipid peroxidation level, as it is
more stable and has a longer half-life (17). The level of
MDA has been shown to increase along with cardiac
necrosis markers c-troponin I and creatine kinase (18), and
has also been found to be significantly higher in patients
with acute myocardial infarction (AMI) compared to
controls (19). 
In an open-chest porcine model, 30 min of ischemia and 
3 h of reperfusion were enough to produce a significant
increased MDA response in myocardial tissue of pigs
subjected to IR, compared to sham-operated pigs (20).
Another open-chest model showed that 60 min of ischemia
and 3 h of reperfusion could produce a significant increase in
plasma MDA levels measured immediately after the
reperfusion period compared to pigs treated with sodium
nitrite (10). The influence of the surgical stress produced in
these open-chest studies as compared to closed-chest studies
might have increased the ROS production, which could be
reflected in elevated lipid peroxidation. However, in one of
the studies (10), the starting MDA level after insertion of the
central venous line and arterial cathetererization was 2.7
nmol/ml, which is much higher than the levels we measured.
This might be due to the spectrophotometric determination
of MDA, which has been shown to result in artificially
elevated MDA levels (21). Human studies measuring MDA
following AMI have shown a significant increase in MDA
levels in patients with AMI compared to controls, measured
6 h from the onset of symptoms (22). 
With regard to inflammatory markers, it is known that
activation of innate immunity also contributes to tissue
damage, thereby determining the infarct size (3, 13), and
elevated levels of the pro-inflammatory cytokine IL6 have
proven to be an independent risk factor of increased
mortality in patients with acute coronary syndrome (23),
predictive of recurrent vascular instability and associated
with in-hospital adverse prognosis (24), and related to death
in patients with acute coronary syndrome (25). A significant
elevation of the anti-inflammatory cytokine IL10
accompanies the peripheral immune responses of AMI (26),
and IL10 is considered an independent predictor of long-term
adverse cardiovascular outcomes in patients with acute
coronary syndrome (27). There are, however, no closed-chest
porcine models examining the cytokine response following
myocardial IR. 
With our setup, we were unable to produce an oxidative
stress response or an inflammatory response that could be
measured in the systemic circulation with the chosen
biomarkers. This could be due to several reasons regarding
both the duration of the ischemic and the reperfusion
periods, and administration of the intervention.
The ischemic period of 45 min was in accordance with
previous studies with regard to infarct size (28, 29).
However, the present study focused only on biomarkers in
the systemic circulation, thus an explanation might be that
we did not include enough animals (type II error). However,
the post-hoc sample-size calculation revealed we had
included enough animals to test the secondary outcomes.
However, most patients present with longer periods of
ischemia, ranging from 3 to 12 h, hence it could be relevant
to subject the animal model to a longer period of ischemia
(30). Thus, the short ischemic period could be a reason why
we did not see a systemic response.
Another reason might be that in our setup, acute coronary
occlusion is mechanically induced in healthy coronary
arteries. AMI is an acute inflammatory condition and in most
patients with this condition, acute coronary occlusion is due
to thrombus formation at a site of a ruptured coronary
atherosclerotic plaque (30). Furthermore, it has been shown
in both humans and animals that aging might augment ROS
formation after myocardial IR (31). 
With regard to the reperfusion period, this may have been
too short in order to obtain a systemic response. In
myocardial tissue, MDA has been found up to 14 days after
the start of reperfusion (32). However, elevated MDA levels
have also been found in pigs 2 to 3 h after the start of
reperfusion (10). These MDA levels were reported in an
open-chest porcine model, thus the response might have been
augmented by the surgical stress owing to this method. In
our set-up, it is possible that we did not see a response in the
inflammatory response due to the short reperfusion period.
For both IL1β and IL6, there seemed to be an increase in the
in vivo 28: 483-488 (2014)
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placebo group at 4 h of reperfusion (Figure 2). Although this
was not significantly different from that of the melatonin
group, it might be indicative of an incipient increase in the
systemic inflammatory response. 
With respect to the intervention, we administered the
melatonin intra-coronarily at the time of reperfusion, thereby
ensuring a high concentration in the myocardium at risk and
allowing melatonin to work at the site of the injury.
Administration prior to ischemia might have yielded a better
outcome for the melatonin-treated group (33), but although
this is feasible in a closed-chest porcine model, it would be
too far from imitating a clinically relevant situation as it is
not possible to predict the time of occurrence of myocardial
infarctions in humans.
In conclusion, melatonin treatment did not result in a
difference in the markers of inflammatory and oxidative
stress, nor in the markers of myocardial damage compared
with placebo. 
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